Business

Powered by
 
Canadian-Related Releases

Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition

  • First insights from IntroDia™, the largest multinational survey of its kind, are presented at the American Diabetes Association's (ADA) 74th Scientific Sessions®
  • Physicians believe early conversations with people diagnosed with Type 2 Diabetes are crucial, but many report a variety of challenges at the point of diagnosis
  • IntroDia™ is currently ongoing and has been developed by Boehringer Ingelheim and Lilly, in partnership with the International Diabetes Federation (IDF)

INGELHEIM, Germany & INDIANAPOLIS, US--(BUSINESS WIRE)--Non-US and Non-UK

The first insights from IntroDia™ presented at the American Diabetes Association's (ADA) 74th Scientific Sessions®, showed that over three quarters (76-100 percent across 26 countries) of 6,753 physicians surveyed agree that conversations at diagnosis impact the way people with Type 2 Diabetes (T2D) accept their condition and their treatment adherence.1 Despite the importance of these conversations, the preliminary data also indicated many physicians report a variety of challenges during the diagnosis conversations.1

According to data presented, the challenges most commonly reported by physicians during diagnosis conversations are that patients do not keep up with the required changes, returning back to old habits, in addition to physicians not having enough time to carry out these important conversations with patients.1

Most physicians (92 percent) surveyed also indicated they would like tools to help people with T2D sustain behavioural change.

Ms. Anne Belton, Vice President of the International Diabetes Federation, and member of the IntroDia™ Advisory Board commented: “These preliminary results from the IntroDia™ survey build on previous studies, which demonstrated that early conversations have an impact in the management of diabetes and can impact patient outcomes. We look forward to the full results, which will provide a deeper understanding of the challenges and barriers for both physicians and people with Type 2 Diabetes. We hope to then provide support to physicians to help them improve those conversations which we believe will result in better outcomes for people with Type 2 Diabetes.”

The IntroDia™ survey is ongoing, and the next set of results will include insights from people with T2D.

The IntroDia™ survey will include insights from 6,753 physicians and approximately 10,000 people with T2D, and is investigating early T2D conversations. The survey results will be used to develop tools to provide additional support for physicians and people with T2D during their early conversations.

Visit www.introdia.com for more information.

###

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/15_june_2014_diabetes.html

Contacts

Boehringer Ingelheim GmbH
Dr. Petra Kienle
TA Metabolism
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 143877
or
Lilly Diabetes
Molly McCully
Communications Manager
Email: mccully_molly@lilly.com
Phone: +1 317 478 5423

Company Information Center

Boehringer Ingelheim RSS feed for Boehringer Ingelheim